Moderna, Inc.(MRNA)
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest News & Analysis
Moderna Q2 2025 Analysis: Navigating Revenue Decline and Pipeline Expansion | Monexa AI
Moderna faces revenue decline in Q2 2025 amid falling COVID-19 vaccine demand but advances mRNA pipeline with oncology and influenza candidates.
Moderna, Inc. Strategic Pipeline Expansion and Financial Update Analysis
Comprehensive analysis of Moderna's Q2 2025 outlook, pipeline diversification into oncology and vaccines, IBM quantum partnership, and financial metrics impact.
Moderna, Inc. Strategic Growth and Financial Update: Navigating mRNA Diversification and Market Challenges
Explore Moderna's financials, strategic pivot to mRNA diversification, Q2 earnings outlook, and pipeline innovations shaping its market positioning and investor prospects.
Moderna, Inc. Comprehensive Analysis: Strategic Pivot and Financial Insights
Explore Moderna's transition from COVID-19 reliance to a diversified mRNA pipeline with detailed financial analysis and market positioning insights.
Moderna Inc. Pediatric Vaccine Approval and Financial Analysis: Market Impact & Strategic Outlook
Moderna's FDA pediatric vaccine approval expands market reach amid financial challenges and robust pipeline development, shaping MRNA's strategic growth trajectory.
Moderna, Inc. Strategic Vaccine Diversification and Financial Analysis - Monexa AI
Moderna pivots to multi-product vaccine leadership with mRNA innovation amid significant financial restructuring and competitive challenges.
Moderna, Inc. Market Analysis: mRNA-1010 Flu Vaccine Advances and Financial Overview
Moderna's mRNA-1010 flu vaccine shows 26.6% higher efficacy in Phase 3, signaling strategic growth in respiratory vaccines amid financial recalibration.
Moderna, Inc. (MRNA) Market Analysis: Strategic Shifts Amid Financial Challenges
Moderna's stock rises +6.20% on strategic pivots despite FY2024 net loss of -$3.56B. Explore financials, competitive landscape, and future outlook for investors.
Moderna, Inc. Market Update: mRNA-1010 Flu Vaccine Efficacy Boosts Growth Prospects
Moderna's mRNA-1010 flu vaccine shows 26.6% superior efficacy, fueling market entry and enhancing its mRNA platform validation amid financial recovery challenges.
Moderna, Inc. Market Analysis: mRNA-1010 Flu Vaccine Efficacy & Financial Impact
Moderna's mRNA-1010 flu vaccine shows 26.6% superior efficacy in Phase 3 trials, poised to disrupt the $7B+ influenza market and influence MRNA's financial trajectory.
Moderna (MRNA) RSV Vaccine Expansion: Market Impact & Strategic Pivot
Moderna's RSV vaccine receives expanded FDA approval, targeting 45M at-risk adults, amidst CDC caution and market volatility.
Moderna's Regulatory Wins & Market Headwinds: An [MRNA](/dashboard/companies/MRNA) Analysis
Moderna's RSV vaccine approval for younger adults signals growth, yet stock volatility persists amid CDC advisory panel changes and fierce market competition.
Moderna: Navigating Revenue Decline and Pipeline Growth in 2025
Moderna faces a pivotal transition in 2025, navigating sharp revenue declines and regulatory shifts while investing heavily in a diversified pipeline.
Moderna's Strategic Pivot: FDA Approval, Financials, and Regulatory Headwinds
Moderna navigates regulatory shifts, political challenges, and market volatility, highlighting the strategic implications for investors.
Moderna (MRNA): Stock Decline, Pipeline Expansion, and Future Outlook
Moderna faces challenges including a Q1 2025 stock decline and regulatory uncertainty, but opportunities exist in pipeline expansion and the mRNA vaccine market.
Moderna (MRNA): Insider Buying, Patent Battles, and the Future of mRNA
Moderna navigates insider buying, patent battles, and mRNA cancer vaccine potential. Success hinges on market capitalization and financial sustainability.
Moderna (MRNA): Decoding the Stock Surge, Patent Disputes, and mRNA Vaccine Race
Moderna's (MRNA) stock is surging amid insider buying and patent rulings, but faces competition and cash burn challenges. A deep dive into its prospects.
Moderna (MRNA) Analysis: Cancer Vaccine, Patents, and Financials
Moderna's stock faces volatility despite insider buying and cancer vaccine progress. Patent battles and revenue shifts create uncertainty. A comprehensive analysis.
Moderna's Crossroads: Patent Battles, RSV Market Entry, and Funding Challenges
Moderna faces patent lawsuits and funding uncertainty despite UK approval of its RSV vaccine. A deep dive into challenges and opportunities.
Moderna (MRNA): Funding, Competition, and mRNA Vaccine Future
Moderna faces funding scrutiny and rising mRNA competition. Cost cuts, political shifts, and pipeline updates shape its future. Analyst outlook mixed.
Moderna (MRNA): Navigating the Post-Pandemic Vaccine Market in 2025
Moderna is navigating a post-pandemic market with cost cuts and pipeline diversification amid competition and government funding uncertainties. Key developments and strategic implications analyzed.
Moderna (MRNA) Pipeline: RSV Vaccine, Cancer Therapies, and Financial Outlook
Analyzing Moderna's (MRNA) pipeline, including RSV and cancer vaccines, financial strategies, and international market performance. Get the latest insights on MRNA stock and industry trends.
Moderna (MRNA): Analyzing Pipeline Progress, Financial Health, and Market Trends
Moderna (MRNA) navigates a dynamic market influenced by emerging diseases, competition, and analyst views. Pipeline progress and revenue are key.
Moderna Announces Major Business Developments | Latest Industry News
Moderna faces mixed analyst sentiment amid pipeline advancements and financial adjustments, influencing investor strategies.
Moderna Navigates Market Challenges: Pipeline Expansion and Financial Outlook
Moderna faces mixed investor sentiment as pipeline prospects compete with declining COVID-19 vaccine revenue, shaping intraday market dynamics and future outlook.
Moderna's Next Chapter: Post-COVID Challenges & Vaccine Hopes
A comprehensive analysis of Moderna’s mixed Q4 2024 results, cost-cutting, and diversified pipeline amid declining COVID-19 vaccine sales.
Moderna's Q4 2024 Earnings: Mixed Financial Results
Moderna's Q4 2024 earnings beat revenue estimates amid higher losses and active pipeline diversification, revealing both challenges and opportunities.